Vera’s Atacicept Passes Phase II IgAN Trial But Data Pale Beside Chinook’s Pipeline Rival
Pivotal Trial Plans Underway
The US biotech’s dual cytokine inhibitor has hit significance in a mid-stage trial with plans underway for a Phase III study, but concerns about its lacklustre efficacy when compared with a rival candidate from Chinook have taken the wind out of its sails.
You may also be interested in...
The US firm is shifting its focus to IgAN after a promising new prespecified analysis of its Phase II trial of atacicept lifted hopes for the product’s prospects as compared with a key rival candidate.
The firms’ Orserdu has won a US thumbs up for the treatment of ESR1-mutated advanced or metastatic breast cancer, marking a positive breakthrough for the challenging SERD drug class.
The US biotech’s lead candidate missed the mark in a Phase III hospital-related pneumonia trial due to low recruitment affected by macroeconomic headwinds but analysts retain high hopes for another upcoming study.